Precision BioSciences, Inc. (NASDAQ:DTIL) is a leading biotechnology company that specializes in developing gene editing technologies aimed at treating genetic disorders and cancers. Utilizing its proprietary ARCUS genome editing platform, Precision BioSciences strives to create precise and targeted therapies that can modify DNA effectively.

The company is positioned in a competitive landscape, contending with peers such as Homology Medicines, Inc. (FIXX), Gossamer Bio, Inc. (GOSS), and Alector, Inc. (ALEC). When assessing the financial efficiency of Precision BioSciences, key metrics such as the Return on Invested Capital (ROIC) and the Weighted Average Cost of Capital (WACC) are crucial. The company's ROIC is -38.88%, while its WACC is 8.61%, leading to a ROIC to WACC ratio of -4.51. This negative ratio highlights the company's challenges in generating returns that surpass its cost of capital, indicating potential inefficiencies in how capital is utilized within the organization.

In comparison, Homology Medicines exhibits a more pronounced negative financial efficiency, with a ROIC of -48.90% and a WACC of 5.12%, resulting in a ROIC to WACC ratio of -9.55. This suggests even greater difficulties in surpassing the cost of capital. Conversely, Alector, Inc. presents a ROIC to WACC ratio of -7.33, with a ROIC of -47.54% and a WACC of 6.48%, indicating similar challenges.

Among its peers, Gossamer Bio, Inc. demonstrates the least negative ratio, with a ROIC to WACC ratio of -2.46, suggesting it is closer to covering its cost of capital and indicating relatively better capital efficiency.